Elite Pharma ANDA Filing for Anticoagulant
Decision brief
Answer first · skim in under a minute
Structured plan for Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product
Elite Pharmaceuticals (OTCQB: ELTP) submitted an Abbreviated New Drug Application to the FDA on June 1, 2026 for a generic anticoagulant, citing $26 billion in branded sales for the twelve months ending March 2026 and no generic on the market. The Northvale, New Jersey specialty generics firm still must clear Orange Book patents and exclusivities before any launch.
Contents10 sections
Key Takeaways
- Elite filed an FDA ANDA for a generic anticoagulant on June 1, 2026, per its Form 8-K exhibit press release.
- IQVIA branded sales for the twelve months ending March 2026 were cited at $26 billion, with no generic currently marketed.
- Unexpired Orange Book patents and exclusivities remain the gating path to approval and commercialization.
- Competitive Generic Therapy designation could accelerate review if FDA finds inadequate generic competition.
What did Elite announce about the anticoagulant ANDA?
On June 1, 2026, Elite Pharmaceuticals said it submitted an Abbreviated New Drug Application (ANDA) for a generic drug in the anticoagulant class. The company did not disclose the reference listed drug name in the announcement.
According to Elite’s SEC-furnished press release, Exhibit 99.1 to its June 2026 Current Report, IQVIA reported branded product sales of $26 billion for the twelve months ending March 2026. Elite also stated there is no generic product on the market for the referenced brand.
How do Orange Book patents affect approval timing?
Elite said the brand has unexpired patents and exclusivity listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, known as the Orange Book. That listing is the official public source for patent and exclusivity data tied to approved drugs.
Under Hatch-Waxman practice, an ANDA that challenges listed patents typically uses a Paragraph IV certification. Brand holders often sue within 45 days of notice, which can trigger a 30-month stay on final approval. Elite did not publish the specific patent numbers or certification type in the June 1 release, so the litigation path remains unconfirmed in primary filings.
What is Competitive Generic Therapy and why it matters
FDA’s Competitive Generic Therapy (CGT) pathway can offer expedited review and, on approval, 180 days of shared exclusivity for products with inadequate generic competition. Because Elite said no generic is currently marketed for the reference product, CGT may be relevant if the company seeks and receives that designation.
CGT does not erase Orange Book patents. It can compress FDA review time and improve launch economics once patents and exclusivities are resolved, but it is not a substitute for bioequivalence, manufacturing, or legal clearance.
- Announcement date: June 1, 2026
- Branded sales cited: $26 billion (T12M ending March 2026, IQVIA via Elite)
- Ticker: OTCQB ELTP; manufacturing base: Northvale, NJ
- Status: ANDA submitted — not approved
What does the filing mean for BD teams and investors?
For business development teams, the filing is a pipeline signal rather than a near-term deal catalyst. Elite historically markets products under the Elite Laboratories label and through licensing with third-party distributors. An eventual approval could therefore surface as a licensing or distribution opportunity rather than a fully owned launch.
Investors should separate market size from path-to-cash. A $26 billion branded class with no generic is attractive on paper, but unexpired patents, possible 30-month stays, and ANDA complete-response risk can push commercialization years to the right. Elite’s own release warned that approval and commercialization depend on successful FDA review and addressing patents and exclusivities.
How does Elite typically commercialize niche generics?
Elite develops, manufactures, and distributes niche generic products, with emphasis on immediate-release and controlled-release solid oral dosage forms. The Northvale facility is described as cGMP-compliant and DEA-registered, which supports controlled-substance as well as conventional generics manufacturing.
Relative to large generic houses, Elite is smaller. That scale can favor focused niche filings, but it also raises questions about prolonged Paragraph IV litigation budgets. Licensing after approval can transfer commercial risk to a larger partner while Elite retains development economics.
What remains unproven after the June 1 disclosure?
The reference listed drug identity is undisclosed, so analysts cannot yet map exact Orange Book patents, exclusivity expiry dates, or Paragraph IV suit risk. Elite has not published a PDUFA-style goal date for this ANDA, CGT status, or any settlement framework. Claims about first-to-file status, specific DOAC molecule targeting, or launch-year revenue should be treated as unsupported until named in a primary filing.
Related NovaPharma coverage
- FDA approves Vertex Journavx for acute pain
- Biogen and Eisai expand Leqembi access
- FDA approves Dupixent for COPD
Frequently Asked Questions
What did Elite Pharmaceuticals announce on June 1, 2026?
Elite Pharmaceuticals announced that it submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration for a generic anticoagulant product. The company did not name the reference listed drug but cited IQVIA branded sales of $26 billion for the twelve months ending March 2026 and said no generic is on the market.
Is the Elite anticoagulant ANDA an FDA approval?
No. An ANDA filing is a request for approval, not an approval. Elite stated that commercialization depends on FDA review success and on addressing unexpired patents and exclusivities listed in the FDA Orange Book.
Why do Orange Book patents matter for this anticoagulant filing?
The FDA Orange Book lists patents and exclusivities for approved drugs. Elite said the branded reference product still has unexpired patents and exclusivity, so approval timing will depend on Paragraph IV litigation outcomes, exclusivity expiry, or both.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Anticoagulant.
Unlock full calendar →Elite Pharmaceuticals, Inc. pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
